PTK2 and neoplasm: This drug also exhibits a suppressing effect through various pathways, such as MMPs (Sun et al., 2007b), FAK (Sun et al., 2009), and PAR1/NF-kB/miRNA-17 (Meng et al., 2014; Qin et al., 2015; Zhong et al., 2017) to target tumor cells.